Crizotinib

Product Name:Crizotinib
Synonyms:PF 02341066 - Crizotinib | PF 2341066;Crizotinib (PF2341066);PF-02341066 Crizotinib;3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine;k-ras(g12c) inhibitor 6 NA Crizotinib;Crizotinib, >=98%;3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridin;3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-Pyridinamine
CAS:877399-52-5
MF:C21H22Cl2FN5O
MW:450.343
EINECS:638-814-9
Product Categories:Anti-cancer & immunity;-;Inhibitor;Aromatic;Chiral Reagents;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pfizer Compounds;Pharmaceuticals
Type:Antineoplastic Agents
Usage:Animal Pharmaceuticals
Appearance:White powder
Purity:99%
Grade Standard:Medicine Grade
Package:1g;100g;500g;1Kg/Foil bag 25kg/drum, 200kg/drum
Shipping methods:By Courier, by air or by sea
Place of Origin:China
Storage:Cool Dry Place
Shelf Life:2 years
Description:In August 2011, the United States FDA approved crizotinib (PF- 02341066) for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC). Crizotinib is a dual ATP competitive inhibitor of tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50=8 nM) and ALK (cellular IC50=20 nM), both of which are important targets for cancer chemotherapy. When crizotinib was tested for selectivity versus other kinases it was found to have enzyme IC50's within 100-fold multiples of c-MET for 13 of the 120 kinases tested. In cellular assays, crizotinib was found to inhibit RON (recepteur d’origine nantais) kinase with a 10-fold selectivity window over c-MET.
Uses:Crizotinib is a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Crizotinib is a potential antitumor agent.